A Phase II, double-blind, parallel-group comparison study of S-556971 in patients with dyslipidemia
Phase 2
- Conditions
- Dyslipidemia
- Registration Number
- JPRN-jRCT2080222525
- Lead Sponsor
- SHIONOGI & CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with dyslipidemia classified into category I and category II for primary prevention defined by Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
Exclusion Criteria
Patients with secondary dyslipidemia.
Patients with severe hepatic, renal, cardiac, respiratory, or blood disorders.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy<br>Safety
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which S-556971 modulates lipid metabolism in dyslipidemia patients?
How does S-556971 compare to statins and PCSK9 inhibitors in managing LDL cholesterol levels in dyslipidemia?
What biomarkers are associated with response to S-556971 in patients with familial hypercholesterolemia or metabolic syndrome?
What are the potential adverse events of S-556971 and how do they compare to other lipid-lowering agents?
Are there any combination therapies involving S-556971 and ezetimibe or bile acid sequestrants for dyslipidemia treatment?